Form 4: Seres Therapeutics Director Claire Fraser Granted Stock Options

Seres Therapeutics, Inc. Director Claire Fraser was granted 6,452 stock options with an exercise price of $10.71, vesting quarterly over one year.

Summary

• Claire Fraser, a Director of Seres Therapeutics, Inc. (MCRB), was granted 6,452 stock options.
• The options have an exercise price of $10.71 per share.
• The grant date for these options was July 1, 2025.
• The options will vest in four equal quarterly installments, beginning October 1, 2025, and continuing on January 1, 2026, April 1, 2026, and July 1, 2026.
• Vesting is contingent upon Claire Fraser's continued service on the Board as a non-employee director through each applicable vesting date.
• The options have an expiration date of July 1, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine stock option grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain any negative or highly positive news regarding company operations or financial performance.

Positives

• The grant of stock options aligns the interests of Director Claire Fraser with those of shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for non-employee directors, indicating normal corporate governance practices.

Negatives

• No immediate negative implications are apparent from this routine stock option grant.

Risks

• The vesting of the stock options is subject to the reporting person's continued service on the Board as a non-employee director through the applicable vesting dates.
• The value of the options is dependent on the future stock price of Seres Therapeutics, Inc. exceeding the exercise price of $10.71.

Future Outlook

The stock options granted to Director Claire Fraser are set to vest in four equal quarterly installments over the next year, contingent on her continued service, aligning future compensation with company performance.

Industry Context

The grant of stock options to a non-employee director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice across publicly traded companies, including those in the biotechnology sector.
• The vesting schedule of four equal quarterly installments over one year is a common structure for director equity grants, similar to practices observed at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, though specific grant sizes and exercise prices vary based on company size, performance, and individual roles.
• The 10-year expiration period for the options is also typical for such grants in the industry.

Related Party Transactions

• The grant of 6,452 stock options to Claire Fraser, a Director of Seres Therapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this specific filing.
• Customers: No direct impact on customers is indicated by this specific filing.
• Suppliers: No direct impact on suppliers is indicated by this specific filing.
• Creditors: No direct impact on creditors is indicated by this specific filing.

Next Steps

• The stock options will vest in quarterly installments on October 1, 2025, January 1, 2026, April 1, 2026, and July 1, 2026, subject to continued service.
• The options will expire on July 1, 2035.

Key Dates

Keywords

Seres Therapeutics, MCRB, Stock Options, Director Compensation, SEC Form 4, Insider Trading, Equity Grant, Vesting Schedule